- Home
- AMZE vs SNGX Comparison
AMZE vs SNGX Comparison
Compare AMZE & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMZE
- SNGX
- Stock Information
- Founded
- AMZE 2019
- SNGX 1987
- Country
- AMZE United States
- SNGX United States
- Employees
- AMZE N/A
- SNGX N/A
- Industry
- AMZE Beverages (Production/Distribution)
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- AMZE Consumer Staples
- SNGX Health Care
- Exchange
- AMZE Nasdaq
- SNGX Nasdaq
- Market Cap
- AMZE 6.6M
- SNGX 6.5M
- IPO Year
- AMZE 2021
- SNGX 1987
- Fundamental
- Price
- AMZE $0.30
- SNGX $1.93
- Analyst Decision
- AMZE
- SNGX
- Analyst Count
- AMZE 0
- SNGX 0
- Target Price
- AMZE N/A
- SNGX N/A
- AVG Volume (30 Days)
- AMZE 127.8K
- SNGX 18.4K
- Earning Date
- AMZE 05-20-2025
- SNGX 05-09-2025
- Dividend Yield
- AMZE N/A
- SNGX N/A
- EPS Growth
- AMZE N/A
- SNGX N/A
- EPS
- AMZE N/A
- SNGX N/A
- Revenue
- AMZE $254,711.00
- SNGX $2,342.00
- Revenue This Year
- AMZE N/A
- SNGX N/A
- Revenue Next Year
- AMZE N/A
- SNGX N/A
- P/E Ratio
- AMZE N/A
- SNGX N/A
- Revenue Growth
- AMZE N/A
- SNGX N/A
- 52 Week Low
- AMZE $0.25
- SNGX $1.68
- 52 Week High
- AMZE $1.25
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- AMZE N/A
- SNGX 49.95
- Support Level
- AMZE N/A
- SNGX $1.86
- Resistance Level
- AMZE N/A
- SNGX $1.97
- Average True Range (ATR)
- AMZE 0.00
- SNGX 0.09
- MACD
- AMZE 0.00
- SNGX 0.01
- Stochastic Oscillator
- AMZE 0.00
- SNGX 70.59
About AMZE Amaze Holdings Inc. Common Stock
Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).